SIGA Technologies, Inc. to Sell 1.7 Million Courses of ST-246(R) to National Stockpile Under Modified Biomedical Advanced Research and Development Authority (BARDA) Contract

NEW YORK, June 27, 2011 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA) announced today that the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services (BARDA) has advised that the protest filed against the contract it awarded to SIGA for the sale of SIGA's smallpox antiviral ST-246® has been withdrawn following execution of a contract modification by BARDA. As a result, the stay on performance of the contract, originally awarded last month, has been lifted.